Stock fact sheet · data as of

Electromed, Inc. (ELMD): fair value, margin of safety and Wheel Score

Healthcare · Medical - Devices · United States · High Growth

Close28.03
GLS fair value28.568 of 9 models
Margin of safety+2%price below fair value
Wheel Score67Goodout of 100
Health7/9Piotroski F-score
Moat7.8/10GLS 10-year score
Market cap$232M57k shares a day
Implied vol.60%near-the-money, 20-60 d
P/E20.5EPS 1.37
Dividend yieldnone
Beta0.46moves less than the market
Next earnings11 Nov 2026in 26 days (after the close)

Is ELMD undervalued?

ELMD closed at 28.03 on 16 Oct 2026 against a GLS average fair value of 28.56 - 1.9% below fair value, which our screens read as "fairly priced". 3 of 8 models are above the current price. There is no discount to lean on here, so the margin of safety is not the reason to look at the stock.

The 8 models disagree widely: Lynch gives 5.47 while GLS Growth gives 83.70. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.

The nightly engine files ELMD under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.

Nine valuation models for ELMD

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF13.48-52%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number14.17-49%The most a defensive investor pays for the earnings and book value per share
Graham Growth22.06-21%Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields
Lynch5.47-80%EPS × the earnings growth rate (PEG of 1), growth capped at 25%
GLS Growth83.70+199%EPS compounded ten years at the blended growth rate, discounted back at 15% a year
10 Cap30.08+7%Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%
Payback Time44.32+58%Eight years of compounded free cash flow: the price at which the business pays for itself
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV15.19-46%Earnings power value: current EPS capitalised at 9% with no growth
Zombie (liquidation)5.44-81%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target48.50+73%Analysts' average 12-month price target. Not in the average

Quality and financial health

On financial health ELMD scores 7/9 (Piotroski): most of the nine tests - positive earnings and cash flow, falling debt, rising margins and turnover - are passed, which is the kind of balance sheet a wheel trader is happy to be assigned. The GLS Moat score is 7.8 out of 10, built from ten years of revenue, earnings, margins, cash flow, share count and returns on capital scored for consistency - a high reading that points to a durable business.

Returns on capital are high - ROIC 20.9%, ROE 20.9%, ROA 17.1% - with debt at 0.00 times equity and a free-cash-flow yield of 4.0%.

Electromed, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Hospital 85%, Other 15% (quarter Q2 FY2025).

Institutional ownership scores 7/10, insider activity 2/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score7 / 9ROIC20.9%
GLS Moat7.8 / 10ROE20.9%
Debt / equity0.00ROA17.1%
Free-cash-flow yield4.0%Payout ratio0%
Institutions7 / 10Insiders · Congress2 · 5 / 10

Wheel Score 67: Good

ELMD scores 67 out of 100 on the Wheel Score (Good band, 65-79). The score blends the margin of safety (Value, 13/25), Piotroski health (16/20), the GLS moat (12/15), the option premium on offer (20/20) and how easily the stock trades (6/20). Stability (6/20) is the part holding the score back.

Implied volatility is 60% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is thin - 415 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.

Volume runs at 57k shares a day on a market cap of $232M, with a beta of 0.46 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.

PartPointsFrom
Value13 / 252% margin of safety
Health16 / 20Piotroski 7/9
Moat12 / 15moat 7.8/10
Premium20 / 20implied volatility 60%
Stability6 / 2057k shares/day, $232M cap, beta 0.46

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 11 Nov 2026 (after the close), 26 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Devices

The 12 companies below are the closest to Electromed, Inc. by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
TLSI
TriSalus Life Sciences, Inc.
3.90--33Weak$240M
PROF
Profound Medical Corp.
6.62--45Weak$242M
TMCI
Treace Medical Concepts, Inc.
4.04--37Weak$263M
CATX
Perspective Therapeutics, Inc.
2.340.1388-1585%22Weak$267M
QSI
Quantum-Si incorporated
1.390.0998-1292%20Weak$277M
INFU
InfuSystem Holdings, Inc.
13.9215.72+11%71Good$277M
RXST
RxSight, Inc.
4.52--43Weak$188M
CLPT
ClearPoint Neuro, Inc.
9.64--44Weak$294M
AVHHL
AVITA Medical, Inc.
2.25--27No options$304M
INGN
Inogen, Inc.
6.30--42Weak$167M
RCEL
Avita Medical Inc.
13.10--43Weak$325M
CV
CapsoVision, Inc.
6.45--29No options$343M

⚖ Compare ELMD with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about ELMD

Is ELMD undervalued right now?

Not meaningfully: at 28.03 the stock trades within a few percent of the GLS average fair value of 28.56 (1.9% below fair value, data as of 16 Oct 2026).

What is the Wheel Score of ELMD and what does it mean?

ELMD scores 67 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for ELMD?

28.56 per share as of 16 Oct 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Electromed, Inc. report earnings next?

The next earnings report is due on 11 Nov 2026 (after the close), 26 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does ELMD have listed options, and how liquid are they?

Yes. The nightly snapshot found 106 listed contracts with 415 open interest across all expiries and implied volatility of 60% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.